Champlain Investment Partners LLC Has $62.64 Million Stock Holdings in Hologic, Inc. $HOLX

Key Points

• Champlain Investment Partners LLC has reduced its stake in Hologic, Inc. by 7.8% during the first quarter, now holding about 1,014,070 shares valued at $62.6 million.
• Hologic's quarterly earnings exceeded expectations, posting an earnings per share (EPS) of $1.08 against an estimate of $1.05, with revenue of $1.02 billion.
• Analyst ratings for Hologic are largely positive, with a consensus rating of "Moderate Buy" and an average target price of $78.00.

Champlain Investment Partners LLC reduced its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,014,070 shares of the medical equipment provider's stock after selling 85,815 shares during the quarter. Champlain Investment Partners LLC owned 0.46% of Hologic worth $62,639,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. increased its position in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after acquiring an additional 1,692,177 shares during the period. Invesco Ltd. increased its position in Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after acquiring an additional 764,573 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Hologic by 1.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after acquiring an additional 69,878 shares during the period. Ameriprise Financial Inc. increased its position in Hologic by 0.8% in the 1st quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after acquiring an additional 29,133 shares during the period. Finally, Northern Trust Corp increased its position in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after acquiring an additional 668,086 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Stephens lowered their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Morgan Stanley boosted their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Evercore ISI boosted their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Hologic currently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Price Performance

Shares of HOLX traded up $0.50 during midday trading on Monday, reaching $67.12. The stock had a trading volume of 1,080,191 shares, compared to its average volume of 1,681,669. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The firm's 50 day moving average price is $66.15 and its 200-day moving average price is $62.49. The company has a market capitalization of $14.93 billion, a P/E ratio of 27.85, a P/E/G ratio of 2.44 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.